🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The Butler Family Foundation is raising money for mesothelioma research with an online auction of some very cool items/experiences. We are very grateful for their continued support! Get yourself some court-side Knicks tickets and support Meso research! butlerfoundation.betterworld.org/auctions/butle…

Come learn more about our work tomorrow at 1:00pm at #cellbio2023 in the Subgroup: Energy and Metabolism in Time and Space . See you in Boston!

PhD candidate Nate Shannon presenting his exciting data in which ERK1/2 activity is dysregulated in response to perinuclear mitochondrial clustering via Miro1 deletion. Great work, Nate!

Our team presenting our MITOPE phase 2 study of novel therapies for #mesothelioma and #lungcancer with malignant pleural effusions to #nurses at قطرات المطر education workshop in #London 👏

We are proud to announce we have 2 abstracts accepted for the AACR Annual Meeting 2024 in San Diego. 👏 We will present our posters in session "Other Cellular Mechanisms for Anticancer Drug Action" and "Cellular Stress Responses 1" See you in🌞SD! Cunniff Lab Dean Fennell FRCP

Exciting news! RedoxVT

Happy to share our review with Ed Chouchani on recent advances in cysteine proteomics! @HarvardCellBio Dana-Farber Cancer Biology Department authors.elsevier.com/c/1idmT4sz6MMd…

Happy to announce our abstract has been approved 👏👏 #BTOG24 Our CSO Brian Cunniff, Phd, Cunniff Lab will be presenting "First-in-class peroxiredoxin 3 (PRX3) inhibitors" poster. Stop by the welcome reception Wednesday April 17th, 18:30 – 20:00, say hello or ask questions.

Looking forward to presenting our new data in support of the anti-cancer activity of RSO-021, lots of fresh discoveries! RedoxVT Dean Fennell FRCP UVM Cancer Center

Always an excellent meeting with great science and clinical progress being showcased! RedoxVT UVM Cancer Center RS Oncology

Congrats to RS Oncology for this much deserved recognition at #ASCO24 . Looking forward to Dean Fennell FRCP giving and exciting talk! RedoxVT

Much deserved Dean Fennell FRCP !

#ASCO24 Abstracts have been published! See the short list of rapid oral abstracts in Developmental Therapeutics - Molecularly Targeted Agents & Tumor Biology and you will see our first-in-human phase 1 for RSO-021 Dean Fennell FRCP Cunniff Lab @PRCLeicester tinyurl.com/ASCO24

Excited to see Dean present exciting data around the Phase 1 trial of RSO-021 at #ASCO24. A redox-dependent cancer therapy currently being tested in Phase 2! RedoxVT UVM Cancer Center Dean Fennell FRCP RS Oncology x.com/RSOncologyLLC/…

Come chat at the booth, we have warm cookies!

News from UVM Cancer Center and RedoxVT, the Redox Biology and Pathology Program at #UVMLarnerMed.

PhD Candidate Nate Shannon's first author paper out as a pre-print. Very proud of Nate! Some very interesting DEGs dependent on Miro1 expression and an interesting and evolving cell cycle/ERK1/2 story! UVM Cancer Center RedoxVT #mitochondria biorxiv.org/content/10.110…

Come check out PhD candidate Victoria Gibson discuss the importance of Peroxiredoxin 3 in mesothelioma tumors at #SfRBM2024. SYMPOSIA SESSION 3: Unveiling the Therapeutic Potential: Exploring Redox Signaling from Fundamentals to Drug Targets 2:45pm RedoxVT RS Oncology SFRBM

Congrats to Nate on an excellent thesis!

Congratulations to Dr. Nate Shannon on his recently published manuscript! Lots of exciting findings to follow up on related to Miro1 and mitochondrial positioning. journals.biologists.com/jcs/article/do…